Publicado em 22/12/2011 - Atualizado 26/07/2019

Artigos científicos mais citados na Human Reproduction e Human Reproduction Update


Veja quais foram os artigos mais citados pelas revistas especializadas em Reprodução Humana – Human Reproduction e Human Reproduction Update – até o período.

Ultrasound assessment of the polycystic ovary: international consensus definitions

Publicado em 2003  pela Human Reproduction Update, disponível no Oxfor Journal.


The polycystic ovary syndrome (PCOS) is a heterogeneous condition, the pathophysiology of which appears to be both multifactorial and polygenic. The definition of the syndrome has been much debated. Key features include menstrual cycle disturbance, hyperandrogenism and obesity. There are many extra-ovarian aspects to the pathophysiology of PCOS, yet ovarian dysfunction is central. At a recent joint ASRM/ESHRE consensus meeting, a refined definition of the PCOS was agreed, encompassing a description of the morphology of the polycystic ovary (PCO). According to the available literature, the criteria fulfilling sufficient specificity and sensitivity to define the PCO should have at least one of the following: either 12 or more follicles measuring 2±9 mm in diameter, or increased ovarian volume (>10 cm3). If there is a follicle >10 mm in diameter, the scan should be repeated at a time of ovarian quiescence in order to calculate volume and area. The presence of a single PCO is sufcient to provide the diagnosis. The distribution of follicles and a description of the stroma are not required in the diagnosis. Increased stromal echogenicity and/or stromal volume are specific to PCO, but it has been shown that the measurement of ovarian volume (or area) is a good surrogate for quantification of the stroma in clinical practice. A woman having PCO in the absence of an ovulation disorder or hyperandrogenism (`asymptomatic PCO’) should not be considered as having PCOS, until more is known about this situation. Three-dimensional and Doppler ultrasound studies may be useful research tools but are not required in the definition of PCO. This review outlines evidence for the current ultrasound definition of the polycystic ovary and technical specifications.

A systematic review of tests predicting ovarian reserve and IVF outcome

Publicado em 2006  pela Human Reproduction Update, disponível no Oxfor Journal.


The age-related decline of the success in IVF is largely attributable to a progressive decline of ovarian oocyte quality and quantity. Over the past two decades, a number of so-called ovarian reserve tests (ORTs) have been designed to determine oocyte reserve and quality and have been evaluated for their ability to predict the outcome of IVF in terms of oocyte yield and occurrence of pregnancy. Many of these tests have become part of the routine diagnostic procedure for infertility patients who undergo assisted reproductive techniques. The unifying goals are traditionally to find out how a patient will respond to stimulation and what are their chances of pregnancy. Evidence-based medicine has progressively developed as the standard approach for many diagnostic procedures and treatment options in the field of reproductive medicine. We here provide the first comprehensive systematic literature review, including an a priori protocolized information retrieval on all currently available and applied tests, namely early-follicular-phase blood val- ues of FSH, estradiol, inhibin B and anti-Müllerian hormone (AMH),the antral follicle count (AFC),the ovarian volume (OVVOL) and the ovarian blood flow, and furthermore the Clomiphene Citrate Challenge Test (CCCT),the exogenous FSH ORT (EFORT) and the gonadotrophin agonist stimulation test (GAST),all as measures to predict ovarian response and chance of pregnancy. We provide, where possible, an integrated receiver operating characteristic (ROC) analysis and curve of all individual evaluated published papers of each test, as well as a formal judgement upon the clin- ical value. Our analysis shows that the ORTs known to date have only modest-to-poor predictive properties and are therefore far from suitable for relevant clinical use. Accuracy of testing for the occurrence of poor ovarian response to hyperstimulation appears to be modest. Whether the a priori identification of actual poor responders in the first IVF cycle has any prognostic value for their chances of conception in the course of a series of IVF cycles remains to be estab- lished. The accuracy of predicting the occurrence of pregnancy is very limited. If a high threshold is used, to prevent couples from wrongly being refused IVF, a very small minority of IVF-indicated cases (~3%) are identified as having unfavourable prospects in an IVF treatment cycle. Although mostly inexpensive and not very demanding, the use of any ORT for outcome prediction cannot be supported. As poor ovarian response will provide some information on OR status, especially if the stimulation is maximal, entering the first cycle of IVF without any prior testing seems to be the preferable strategy.

Revised 2003 consensus on diagnostic criteria and long- term health risks related to polycystic ovary syndrome (PCOS)

Publicado em Dezembro de 11  pela Human Reproduction , disponível no Oxfor Journal.


Since the 1990 NIH-sponsored conference on polycystic ovary syndrome (PCOS),it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunction than those defined by the original diagnostic criteria. The 2003 Rotterdam consensus workshop concluded that PCOS is a syndrome of ovar- ian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology. PCOS remains a syndrome and, as such, no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis. Its clinical manifestations may include: menstrual irregularities, signs of androgen excess, and obesity. Insulin resistance and elevated serum LH levels are also common features in PCOS. PCOS is associated with an increased risk of type 2 diabetes and cardiovascular events.

Inscreva-se em nossa newsletter.

Receba mais informações sobre cuidados para a saúde em seu e-mail.

Publicado por: Equipe Fecondare

Filtre por temas:

Filtre pelo formato de conteúdo

Assine nossa newsletter!

    Assine nossa newsletter!

      (48) 3024-2523

      Rua Menino Deus, 63 Sala 302. Baía Sul Medical Center - Centro CEP: 88020-203 – Florianópolis – SC

      Diretor técnico médico: Dr Jean Louis Maillard - CRM-SC 9987 RQE 5605

      LGPD - Lei Geral de Proteção de Dados Pessoais A Clínica Fecondare trata com seriedade, confidencialidade e integridade todos os dados pessoais que se encontram sob a sua responsabilidade. Aqui cuidamos não apenas da sua saúde, mas também do sigilo das informações dos pacientes, colaboradores, médicos, prestadores de serviço e fornecedores. Requisições relacionadas à Lei Geral de Dados Pessoais (LGPD)? Entre em contato com a Clínica Fecondare. E-mail:

      Termos e Serviços
      Política de privacidade
      2024 © Clínica Fecondare - Todos os direito Reservados
      Desenvolvido por esaude